Literature DB >> 12368573

Why do treated hypertensives suffer strokes? An internist's perspective.

Geza Simon1.   

Abstract

Despite widespread treatment of hypertension, stroke continues to be the third leading cause of death in the United States. Antihypertensive therapy is more effective in preventing hemorrhagic strokes than ischemic strokes. In order to understand the reasons why antihypertensive therapy is only partially successful in the eradication of ischemic strokes, differences in the pathogenesis and treatment of subtypes of stroke must be considered. There are three main stroke subtypes of ischemic strokes: small-vessel arteriopathic (lacunar), large-artery atherothrombotic, and cardioembolic. Hypertension is the major cause of lacunar strokes but plays a lesser role in the pathogenesis of atherothrombotic strokes. Antihypertensive therapy prevents the majority of lacunar strokes but may not have a major impact on the occurrence of atherothrombotic strokes. Due to impaired cerebral autoregulation, overtreatment of hypertension, especially in the elderly and in patients with previous strokes, may paradoxically lead to stroke (J-curve). Assuming that the majority of lacunar strokes are prevented by judicious antihypertensive therapy, future therapeutic efforts should concentrate on the prevention of atherothrombotic and cardioembolic strokes. In this regard, refinement of surgical techniques, pharmacologic approaches aimed at plaque stabilization, and the application of transesophageal echocardiography for the diagnosis of embolic strokes (and anticoagulation for a probable source) are promising. Besides the obvious reasons of noncompliance and inadequate therapy, overly aggressive treatment of hypertension in the elderly and stroke mechanisms unrelated to blood pressure may explain the occurrence of strokes despite our efforts to treat hypertension. Copyright 2002 Le Jacq Communications, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12368573      PMCID: PMC8101842          DOI: 10.1111/j.1524-6175.2002.00686.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  52 in total

Review 1.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials.

Authors:  P R Hebert; J M Gaziano; K S Chan; C H Hennekens
Journal:  JAMA       Date:  1997 Jul 23-30       Impact factor: 56.272

2.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

3.  Impaired autoregulation of cerebral blood flow in long-term type I (insulin-dependent) diabetic patients with nephropathy and retinopathy.

Authors:  J Kastrup; S Rørsgaard; H H Parving; N A Lassen
Journal:  Clin Physiol       Date:  1986-12

4.  Effect of antihypertensive treatment on stroke recurrence. Hypertension-Stroke Cooperative Study Group.

Authors: 
Journal:  JAMA       Date:  1974-07-22       Impact factor: 56.272

5.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1997-11-24

6.  Subtypes of ischemic stroke. A hospital-based stroke registry in Taiwan (SCAN-IV).

Authors:  P K Yip; J S Jeng; T K Lee; Y C Chang; Z S Huang; S K Ng; R C Chen
Journal:  Stroke       Date:  1997-12       Impact factor: 7.914

7.  J-shaped relation between blood pressure and stroke in treated hypertensives.

Authors:  Z Vokó; M L Bots; A Hofman; P J Koudstaal; J C Witteman; M M Breteler
Journal:  Hypertension       Date:  1999-12       Impact factor: 10.190

8.  Two clinically distinct lacunar infarct entities? A hypothesis.

Authors:  J Boiten; J Lodder; F Kessels
Journal:  Stroke       Date:  1993-05       Impact factor: 7.914

9.  Cerebral hemodynamics in young hypertensive subjects and effects of atenolol treatment.

Authors:  E Troisi; A Attanasio; M Matteis; M Bragoni; B C Monaldo; C Caltagirone; M Silvestrini
Journal:  J Neurol Sci       Date:  1998-07-15       Impact factor: 3.181

10.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

View more
  4 in total

1.  Hypertension: New treatment target for systolic blood pressure?

Authors:  Richard J Johnson; Laura G Sánchez-Lozada; Bernardo Rodríguez-Iturbe
Journal:  Nat Rev Nephrol       Date:  2009-12       Impact factor: 28.314

2.  Atrial fibrillation and hypertension: do new anticoagulants change the matter?

Authors:  Vivencio Barrios; Carlos Escobar; Alberto Calderon
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-03-27       Impact factor: 3.738

3.  Will we ever wipe out stroke?

Authors:  Ray W Gifford
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Sep-Oct       Impact factor: 3.738

4.  Adiposity and risk of cardiovascular diseases in Japan: secular trend, individual level associations and causal pathway - implications for the prevention of cardiovascular diseases in societies with rapid economic development.

Authors:  Hiroshi Yatsuya; Kazumasa Yamagishi; Hiroyasu Iso
Journal:  EPMA J       Date:  2011-03-27       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.